SG Americas Securities LLC purchased a new position in Singular Genomics Systems, Inc. (NASDAQ:OMIC – Get Rating) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 20,921 shares of the company’s stock, valued at approximately $80,000.
Several other hedge funds have also recently modified their holdings of the business. UBS Group AG lifted its position in shares of Singular Genomics Systems by 4,016.9% in the 1st quarter. UBS Group AG now owns 4,565,720 shares of the company’s stock worth $28,810,000 after purchasing an additional 4,454,819 shares during the period. BlackRock Inc. lifted its position in shares of Singular Genomics Systems by 150.5% in the 1st quarter. BlackRock Inc. now owns 2,830,677 shares of the company’s stock worth $17,862,000 after purchasing an additional 1,700,829 shares during the period. Goldman Sachs Group Inc. lifted its position in shares of Singular Genomics Systems by 21.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,086,255 shares of the company’s stock worth $6,854,000 after purchasing an additional 191,784 shares during the period. Tikvah Management LLC purchased a new stake in Singular Genomics Systems during the first quarter valued at approximately $4,465,000. Finally, State Street Corp lifted its position in Singular Genomics Systems by 163.7% during the first quarter. State Street Corp now owns 515,049 shares of the company’s stock valued at $3,250,000 after acquiring an additional 319,753 shares during the last quarter. Hedge funds and other institutional investors own 54.04% of the company’s stock.
Wall Street Analysts Forecast Growth
A number of equities research analysts recently commented on OMIC shares. The Goldman Sachs Group decreased their target price on shares of Singular Genomics Systems from $3.50 to $3.00 and set a “neutral” rating for the company in a research report on Tuesday, November 8th. Bank of America cut shares of Singular Genomics Systems from a “buy” rating to an “underperform” rating and set a $3.00 target price for the company. in a research report on Wednesday, August 10th. Finally, UBS Group cut shares of Singular Genomics Systems from a “buy” rating to a “neutral” rating and decreased their target price for the company from $10.00 to $4.50 in a research report on Wednesday, August 17th.
Singular Genomics Systems Trading Down 3.7 %
Singular Genomics Systems Profile
Singular Genomics Systems, Inc, a life science technology company, develops next generation sequencing and multiomics technology to build products for researchers and clinicians to advance science and medicine. The company manufactures G4 Instrument, a benchtop next generation sequencer to produce genetic sequencing results, as well as associated menu of consumable kits.
- Get a free copy of the StockNews.com research report on Singular Genomics Systems (OMIC)
- Does ASML’s November Rally Have Staying Power?
- Verra Mobility Stock Has Returned Back to the Station
- Is Advance Auto Parts a Buy After its Earnings Crash?
- BJ’s Wholesale Club: Beware The Sell-Side
- The Next Catalyst For Mullen Automotive Stock Is December 23rd
Receive News & Ratings for Singular Genomics Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Singular Genomics Systems and related companies with MarketBeat.com's FREE daily email newsletter.